Doseskaleringsstudie av CLR 131 hos barn, ungdomar och unga vuxna med återfallande eller refraktära maligna tumörer inklusive men inte begränsat till neuroblastom, rabdomyosarkom, Ewings sarkom och osteosarkom (CLOVER-2)
En öppen etikett, dosupptrappning, effektivitet och säkerhetsstudie av CLR 131 hos barn, ungdomar och unga vuxna med utvalda solida tumörer, lymfom och maligna hjärntumörer
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
Even with standard, highly toxic multimodality therapies and salvage regimen, most pediatric patients with primary metastatic or relapsed solid tumors are confronted with a poor prognosis. For these patients there is currently no accepted successful treatment regimen. There is a need for new drugs, including targeted radiopharmaceuticals, preferably with cancer-specific uptake and broad applicability for these rare pediatric malignancies.
CLR 131 is a radioiodinated therapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted small-molecule compound (CLR1404) is radiolabeled with the isotope iodine-131 (I-131). CLR 131 has demonstrated tumor selective uptake across numerous adult and pediatric cancer cell types. Therapeutic efficacy has been demonstrated in various pediatric and adult-type cancer xenograft models, confirming the ability of CLR 131 to target tumors.
Based on the critical unmet medical need for effective agents with novel mechanisms of action in relapsed pediatric cancers and initial preclinical and clinical experience with radioiodinated CLR1404, Cellectar Biosciences has chosen to assess CLR 131 in a phase 1 pediatric trial.
Studietyp
Studietyp
Inskrivning (Beräknad)
Inskrivning
Fas
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
New South Wales
-
Westmead, New South Wales, Australien, 2145
- Children's Hospital at Westmead
-
-
-
-
California
-
Palo Alto, California, Förenta staterna, 94304
- Lucile Packard Children's Hospital
-
-
New York
-
New York, New York, Förenta staterna, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27708
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Texas Children's Hospital
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53792
- University of Wisconsin Hospital and Clinics
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G1X8
- Hospital for Sick Children
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
All Patients
- Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or radiographically suspected to be relapsed, refractory, or recurrent for which there are no standard treatment options with curative potential. Note: patients with diffuse intrinsic pontine glioma (DIPG) may enroll without histological or cytological confirmation.
- ≥ 2 years of age and ≤ 25 years of age at time of consent/assent
- If ≥ age 16 years, Karnofsky performance status of ≥ 60. If < age 16 years, Lansky performance status ≥ 60
- Platelets ≥ 75,000/µL (last transfusion, if any, must be at least 1 week prior to study registration, and, unless deemed medically necessary, no transfusions are allowed between registration and dosing)
- Absolute neutrophil count ≥ 750/µL
- Hemoglobin ≥ 8 g/dL (last transfusion must be at least 1 week prior to study registration, and, unless deemed medically necessary, no transfusions are allowed between registration and dosing)
- Using the bedside Schwartz formula, estimated GFR (creatinine clearance) > 60 ml/min/1.73m2
- Alanine aminotransferase < 3 × ULN
- Bilirubin < 2 × ULN
- Patients who have undergone autologous or allogeneic bone marrow transplant must be at least 3 months from transplant.
- Patients enrolling at total dose levels > 30 millicurie (mCi)/m2 must have availability or ability to collect an autologous hematopoietic stem cell back-up product prior to CLR 131 administration. At minimum, 2 x 10^6/kg cryopreserved CD34+ cells must be available.
- Patient or his or her legal representative is judged by the Investigator to have the initiative and means to be compliant with the protocol.
Patients with Pediatric Solid Tumor or Lymphoma
- At least 1 measurable lesion with longest diameter of at least 10 mm. Patients with a lesion(s) that are determined to be Metaiodobenzylguanidine (MIBG) or positron emission tomography (PET) positive may be enrolled at the investigator's discretion, even if not associated with a measurable lesion of at least 10 mm. Patients with neuroblastoma who have detectable disease may enroll provided they meet the requirements of the International Neuroblastoma Response Criteria.
- Patients with known brain metastases must have completed any radiotherapy or systemic treatments for brain metastases prior to enrollment; by investigator assessment be considered stable with no new signs or symptoms for at least 1 month, and on a stable dose of steroids (unchanged for three weeks prior to registration or on a steroid tapering regimen).
Patients with Recurrent or Refractory Brain Tumors
- At least 1 measurable lesion with longest diameter of at least 10 mm on any imaging sequence.
- Patients with previously known neurological deficits must be clinically stable at time of enrollment and able to complete all study related procedures. Patients with documented or newly diagnosed neurological deficits will be enrolled at the investigator's discretion.
- If patient receives steroids for neurological symptom control, the dose must be stable (unchanged for three weeks prior to registration) or on a steroid tapering regimen. Initiation of steroids per routine care immediately prior to CLR 131 dosing is acceptable.
Exclusion Criteria:
- Patients receiving active treatment for central nervous system metastases or those that are likely to require active treatment during anticipated participation in this trial. Patients with stable brain metastases treated with steroids may enroll at the investigator's discretion
- For solid tumor and lymphoma patients only, central nervous system involvement unless previously treated with surgery, systemic therapy, or radiotherapy with the patient neurologically stable. Patients with metastatic brain tumors that have been previously treated are allowed, provided the patient is neurologically stable (determined at the investigator's discretion).
- Antitumor therapy or investigational therapy, within 2 weeks of dosing. For certain types of radiation (craniospinal, total abdominal, whole lung [spot irradiation to skull-based metastases is not considered craniospinal radiation for the purposes of this study]), at least 3 months must have elapsed. No washout is required for palliative focal radiation. NOTE: Patients participating in non-interventional clinical trials (i.e., non-drug) are allowed to participate in this trial
- Patients previously treated with iodine-131 (131I)-MIBG who have already received a cumulative I-131 dose > 54 mCi/kg or who would exceed 54 mCi/kg by participating in this trial, are not eligible.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: CLR 131
CLR 131 intravenous administration |
IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of participants with dose limiting toxicities (DLT)
Tidsram: up to 64 days
|
DLT will be assessed by physical examination, vital signs, and laboratory values |
up to 64 days
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Identification of recommended phase 2 dose of CLR 131 in children, adolescents, and young adults
Tidsram: until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
|
Dose and regimen to be used in Phase 2 trials of CLR 131 in children, adolescents, and young adults |
until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
|
|
Determination of preliminary antitumor activity of CLR 131 in children, adolescents, and young adults
Tidsram: through Day 85
|
Response assessment per applicable criteria (e.g., Neuroblastoma Response Criteria (modified); RECIST 1.1; positron emission tomography response criteria in solid tumors (PERCIST); RANO) |
through Day 85
|
|
Determination of therapeutic activity of CLR 131 in children, adolescents, and young adults
Tidsram: up to 22 days post initial infusion
|
Assessment via 131-I/CLR 131 SPECT/CT scans |
up to 22 days post initial infusion
|
|
Determination of event free survival following CLR 131 infusion in children, adolescents, and young adults
Tidsram: 1 month to 5 years
|
Time from first infusion of CLR 131 until progression or recurrence of disease |
1 month to 5 years
|
|
Determination of overall survival following CLR 131 infusion in children, adolescents, and young adults
Tidsram: 1 month to 5 years
|
Time from first infusion of CLR 131 until death due to any reason |
1 month to 5 years
|
|
Determine dosimetry of CLR 131 in children, adolescents, and young adults
Tidsram: up to 15 days post initial infusion
|
Assessment of dosimetry via whole body planar imaging |
up to 15 days post initial infusion
|
Samarbetspartners och utredare
Sponsor
Sponsor
Utredare
Utredare
- Studierektor: Jarrod Longcor, Cellectar Biosciences
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Studiestart
Primärt slutförande (Beräknad)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- lymfom
- osteosarkom
- Ewing sarkom
- ATRT
- glioblastom
- Non-Hodgkin lymfom
- neuroblastom
- medulloblastom
- höggradigt gliom
- rabdomyosarkom
- DIPG
- sarkom
- Wilms tumör
- ependymom
- PNET
- gliosarkom
- sällsynt cancer
- Hodgkins lymfom
- desmoplastisk små rundcellig tumör
- maligna könscellstumörer
- synovialt sarkom
- DSRCT
- diffust-intrinsiskt pontint gliom
- atypisk teratoid rhabdoidtumör
- primitiv neuroektodermal tumör
- gliomatosis cerebri
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Manliga urogenitala sjukdomar
- Njursjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Genetiska sjukdomar, medfödda
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer, körtel och epitel
- Lymfatiska sjukdomar
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Urologiska neoplasmer
- Astrocytom
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neoplasmer i nervsystemet
- Neoplasmer i njurarna
- Neoplastiska syndrom, ärftligt
- Neoplasmer, bindväv och mjukvävnad
- Neuroektodermala tumörer, primitiva, perifera
- Neoplasmer, benvävnad
- Neoplasmer, bindväv
- Neoplasmer i centrala nervsystemet
- Neoplasmer, muskelvävnad
- Neoplasmer, komplexa och blandade
- Myosarkom
- Neoplasmer i hjärnan
- Neoplasmer i hjärnstammen
- Infratentoriella neoplasmer
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Hemiska och lymfsjukdomar
- Diffus Intrinsic Pontine Gliom
- Lymfom
- Glioblastom
- Gliom
- Neuroblastom
- Sarkom, Ewing
- Lymfom, icke-Hodgkin
- Sarkom
- Hodgkins sjukdom
- Sarkom, synovial
- Rabdomyosarkom
- Gliosarkom
- Osteosarkom
- Ependymom
- Medulloblastom
- Neuroektodermala tumörer, primitiva
- Wilms tumör
- Rhabdoid tumör
- Desmoplastisk liten rundcellig tumör
- Neoplasmer, neuroepitelial
- CLR1404
Andra studie-ID-nummer
Andra studie-ID-nummer
- DCL-17-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .